SCHEMBL4217374

SCHEMBL4217374

CCO/C(=C\c1ccc(-c2cccc(NC)c2)nc1)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 4/20 0.41
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
SYK P43405 2/20 0.37
KDM1A O60341 2/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
BAZ2B Q9UIF8 1/20 0.36
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
HTT P42858 1/20 0.36
BTK Q06187 1/20 0.35
ITK Q08881 1/20 0.35
WNT3A P56704 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4217379 1.00 DHODH (0.41) DHODHCYP11B1CYP11B2LMNATP53
SCHEMBL4221571 0.85 DHODH (0.50) DHODHTP53SYKMEN1KMT2A
SCHEMBL4221578 0.85 DHODH (0.50) DHODHTP53SYKMEN1KMT2A
SCHEMBL4209358 0.83 MAPT (0.39) DHODHMAPTSYKKDM4EPOLB
SCHEMBL4209363 0.83 MAPT (0.39) DHODHMAPTSYKKDM4EPOLB
SCHEMBL4217376 0.83 TBXAS1 (0.45) DHODHCYP11B1CYP11B2TP53MAPT
SCHEMBL4210691 0.78 KDM4E (0.39) DHODHMAPTNPC1RAB9AMEN1
SCHEMBL4210700 0.78 KDM4E (0.39) DHODHMAPTNPC1RAB9AMEN1
SCHEMBL67896 0.77 SYK (0.48) DHODHCYP11B1CYP11B2TP53SYK
SCHEMBL1750810 0.76 MAPT (0.39) DHODHMAPTSYKKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383652-B2 Biaromatic compounds that modulate PPAR-receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-02-26 US disclosed
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-08 US disclosed
EP-1943213-A2 PPAR MODULATING BIAROMATIC COMPOUNDS Galderma Research & Development (FR) 2008-07-16 EP disclosed
WO-2007049158-A2 PPAR MODULATING BIAROMATIC COMPOUNDS GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS PPARG, PPARD, PPARA DHODH 2932/4885CYP11B1 97/4885CYP11B2 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.